Pfizer pulls Jarvik spots, vows more "clarity" on spokespeople

Share this article:

Pfizer pulled Lipitor ads featuring Dr. Robert Jarvik and vowed that it is “committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion.”

In a statement, Pfizer's Ian Read, president of worldwide pharmaceutical operations, defended Jarvik, the campaign and DTC but said: “Nevertheless, the way in which we presented Dr. Jarvik in these ads has, unfortunately, led to misimpressions and distractions from our primary goal of encouraging patient and physician dialogue on the leading cause of death in the world – cardiovascular disease.”

“Going forward, we commit to ensuring there is greater clarity in our advertising regarding the presentation of spokespeople,” Read said, adding that future campaigns, “to be launched in several weeks,” will continue to stress the importance of patients talking to their doctors.

Kaplan Thaler Group handles consumer advertising on the brand. From January, 2006 through September, 2007, Pfizer spent $210 million on Lipitor DTC ads, according to TNS Media Intelligence.

The ads became the target of a congressional investigation last month, as Michigan Democratic Representatives John Dingell and Bart Stupak demanded that Pfizer fork over all records pertaining to the campaign, including financial records, contractual arrangements, contracts, emails, correspondence and scripts for TV and print ads featuring Jarvik. Dingell, chairman of the House Committee on Energy and Commerce, and Stupak, chairman of the House Subcommittee on Oversight and Investigations, took particular interest in Jarvik's professional qualifications, taking issue with the fact that he is neither a licensed nor a practicing physician, and his compensation.

The resulting news coverage, including the revelations that Jarvik was promised $1.35 million for his participation in the campaign and that a stunt double was used to portray him rowing across a lake, was embarrassing for Pfizer.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...